RATIONALE: Bronchoalveolar lavage fluid (BAL) from human lung allografts demonstrates the presence of a multipotent mesenchymal stromal cell population. However, the clinical relevance of this novel cellular component of BAL and its association with bronchiolitis obliterans syndrome (BOS), a disease marked by progressive airflow limitation secondary to fibrotic obliteration of the small airways, remains to be determined. OBJECTIVES: In this study we investigate the association of number of mesenchymal stromal cells in BAL with development of BOS in human lung transplant recipients. METHODS: Mesenchymal colony-forming units (CFUs) were quantitated in a cohort of 405 BAL samples obtained from 162 lung transplant recipients. Poisson generalized estimating equations were used to determine the predictors of BAL mesenchymal CFU count. MEASUREMENTS AND MAIN RESULTS: Higher CFU counts were noted early post-transplantation; time from transplant to BAL of greater than 3 months predicted 0.4-fold lower CFU counts (P = 0.0001). BOS diagnosis less than or equal to 365 days before BAL was associated with a 2.11-fold higher CFU count (P = 0.02). There were 2.62- and 2.70-fold higher CFU counts noted in the presence of histologic diagnosis of bronchiolitis obliterans (P = 0.05) and organizing pneumonia (0.0003), respectively. In BAL samples obtained from BOS-free patients greater than 6 months post-transplantation (n = 173), higher mesenchymal CFU counts (≥10) significantly predicted BOS onset in both univariate (hazard ratio, 5.61; 95% CI, 3.03-10.38; P < 0.0001) and multivariate (hazard ratio, 5.02; 95% CI, 2.40-10.51; P < 0.0001) Cox regression analysis. CONCLUSIONS: Measurement of mesenchymal CFUs in the BAL provides predictive information regarding future BOS onset.
RATIONALE: Bronchoalveolar lavage fluid (BAL) from human lung allografts demonstrates the presence of a multipotent mesenchymal stromal cell population. However, the clinical relevance of this novel cellular component of BAL and its association with bronchiolitis obliterans syndrome (BOS), a disease marked by progressive airflow limitation secondary to fibrotic obliteration of the small airways, remains to be determined. OBJECTIVES: In this study we investigate the association of number of mesenchymal stromal cells in BAL with development of BOS in human lung transplant recipients. METHODS: Mesenchymal colony-forming units (CFUs) were quantitated in a cohort of 405 BAL samples obtained from 162 lung transplant recipients. Poisson generalized estimating equations were used to determine the predictors of BAL mesenchymal CFU count. MEASUREMENTS AND MAIN RESULTS: Higher CFU counts were noted early post-transplantation; time from transplant to BAL of greater than 3 months predicted 0.4-fold lower CFU counts (P = 0.0001). BOS diagnosis less than or equal to 365 days before BAL was associated with a 2.11-fold higher CFU count (P = 0.02). There were 2.62- and 2.70-fold higher CFU counts noted in the presence of histologic diagnosis of bronchiolitis obliterans (P = 0.05) and organizing pneumonia (0.0003), respectively. In BAL samples obtained from BOS-freepatients greater than 6 months post-transplantation (n = 173), higher mesenchymal CFU counts (≥10) significantly predicted BOS onset in both univariate (hazard ratio, 5.61; 95% CI, 3.03-10.38; P < 0.0001) and multivariate (hazard ratio, 5.02; 95% CI, 2.40-10.51; P < 0.0001) Cox regression analysis. CONCLUSIONS: Measurement of mesenchymal CFUs in the BAL provides predictive information regarding future BOS onset.
Authors: S A Yousem; G J Berry; P T Cagle; D Chamberlain; A N Husain; R H Hruban; A Marchevsky; N P Ohori; J Ritter; S Stewart; H D Tazelaar Journal: J Heart Lung Transplant Date: 1996-01 Impact factor: 10.247
Authors: B DiGiovine; J P Lynch; F J Martinez; A Flint; R I Whyte; M D Iannettoni; D A Arenberg; M D Burdick; M C Glass; C A Wilke; S B Morris; S L Kunkel; R M Strieter Journal: J Immunol Date: 1996-11-01 Impact factor: 5.422
Authors: H Castro-Malaspina; R E Gay; G Resnick; N Kapoor; P Meyers; D Chiarieri; S McKenzie; H E Broxmeyer; M A Moore Journal: Blood Date: 1980-08 Impact factor: 22.113
Authors: R E Girgis; I Tu; G J Berry; H Reichenspurner; V G Valentine; J V Conte; A Ting; I Johnstone; J Miller; R C Robbins; B A Reitz; J Theodore Journal: J Heart Lung Transplant Date: 1996-12 Impact factor: 10.247
Authors: Peter M Hopkins; Christina L Aboyoun; Prashant N Chhajed; Monique A Malouf; Marshall L Plit; Stephen P Rainer; Allan R Glanville Journal: Am J Respir Crit Care Med Date: 2004-08-05 Impact factor: 21.405
Authors: Michael E Bowdish; Selim M Arcasoy; Jessie S Wilt; John V Conte; Robert Duane Davis; Edward R Garrity; Marshall L Hertz; Jonathan B Orens; Bruce R Rosengard; Mark L Barr Journal: Am J Transplant Date: 2004-07 Impact factor: 8.086
Authors: M I Hertz; C A Henke; R E Nakhleh; K R Harmon; W A Marinelli; J M Fox; S H Kubo; S J Shumway; R M Bolman; P B Bitterman Journal: Proc Natl Acad Sci U S A Date: 1992-11-01 Impact factor: 11.205
Authors: Luis A Ortiz; Frederica Gambelli; Christine McBride; Dina Gaupp; Melody Baddoo; Naftali Kaminski; Donald G Phinney Journal: Proc Natl Acad Sci U S A Date: 2003-06-18 Impact factor: 12.779
Authors: Daniel J Weiss; Daniel Chambers; Adam Giangreco; Armand Keating; Darrell Kotton; Peter I Lelkes; Darcy E Wagner; Darwin J Prockop Journal: Ann Am Thorac Soc Date: 2015-04
Authors: Michael P Combs; Meng Xia; David S Wheeler; Elizabeth A Belloli; Natalie M Walker; Russell R Braeuer; Dennis M Lyu; Susan Murray; Vibha N Lama Journal: J Heart Lung Transplant Date: 2020-04-19 Impact factor: 10.247
Authors: Hong Xia; Vidya Bodempudi; Alexey Benyumov; Polla Hergert; Damien Tank; Jeremy Herrera; Jeff Braziunas; Ola Larsson; Matthew Parker; Daniel Rossi; Karen Smith; Mark Peterson; Andrew Limper; Jose Jessurun; John Connett; David Ingbar; Sem Phan; Peter B Bitterman; Craig A Henke Journal: Am J Pathol Date: 2014-03-13 Impact factor: 4.307
Authors: Natalie M Walker; Linda N Badri; Anish Wadhwa; Scott Wettlaufer; Marc Peters-Golden; Vibha N Lama Journal: Am J Respir Crit Care Med Date: 2012-01-01 Impact factor: 21.405
Authors: Natalie Walker; Linda Badri; Scott Wettlaufer; Andrew Flint; Uma Sajjan; Paul H Krebsbach; Venkateshwar G Keshamouni; Marc Peters-Golden; Vibha N Lama Journal: Am J Pathol Date: 2011-06 Impact factor: 4.307